Skip to main content

Day: April 25, 2024

RevoluGROUP and Bit2Me Announce Strategic Partnership to Enhance Global Payments and Digital Asset Accessibility

Vancouver (Canada), Barcelona and Alicante (Spain), April 25, 2024 (GLOBE NEWSWIRE) — Bitcoinforme SL. (“Bit2Me”) and RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (“RevoluGROUP”) are pleased to announce a strategic partnership with RevoluGROUP wholly owned subsidiary RevoluPAY S.P. (RevoluPAY) and Bit2Me, in the evolution of digital asset accessibility, harnessing the strengths of both entities to offer digital asset management and a seamless payment processing between fiat currencies and digital assets.The collaboration with Bit2Me (executed on April 16th, 2024) represents a mutual commitment to simplifying the user experience while maintaining the highest security and compliance standards. By leveraging RevoluGROUP’s advanced payment solutions and Bit2Me’s extensive expertise...

Continue reading

Safe & Green Holdings Announces it Has Entered Into an Agreement to Produce Four Modular Electrical Distribution Centers as Part of a Multi-Unit Order for a Client Serving the Big Box Retailer Market

Miami, FL, April 25, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, announced today that Safe and Green Holdings has entered into an agreement to manufacture four container based electrical distribution centers as part of a multi-unit order for a client serving the big box retailer market. A modular electrical distribution center offers a flexible and customizable solution for distributing electricity from a single source to multiple destinations. The unit excels in versatility and dependability, efficiently managing and distributing electrical power, and is easily adaptable to evolving technologies and escalating power requirements. Paul Galvin, Chairperson and CEO of Safe and Green Holdings...

Continue reading

Verizon gives customers more peace of mind with enhanced Home Device Protection service

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) — Research has shown that the average U.S. household has over $11,000 worth of home technology products1. As the number of devices we rely on at home continues to increase, so does the need to protect them. For $25/month (plus applicable taxes), customers can repair and replace an unlimited number of eligible home technology products such as TVs, tablets, laptops, wearables and gaming devices with Verizon Home Device Protect.2 Beginning April 25, customers with Verizon Home Device Protect will gain access to new benefits and services at no additional cost, including:Expanded Protection: Coverage now includes Wi-Fi-enabled home healthcare tech (pulse oximeters, EKGs, blood pressure monitors), smart mops and vacuums, pet-care items and advanced gaming accessories. Second Residence Coverage:...

Continue reading

SYLA Technologies Announces Gain on Sales of Investment Securities

TOKYO, April 25, 2024 (GLOBE NEWSWIRE) — SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of the largest membership real estate crowd-funding platform in Japan, Rimawari-kun, announced the sale of a segment of its investment securities holdings, resulting in a profit of 96 million yen. On April 11, 2024, SYLA executed the sale of one listed stock from its investment portfolio, resulting in a total gain on sales of 96 million yen. SYLA intends to utilize the net proceeds to enhance asset efficiency and fortify the company’s financial structure. The sale will be recorded as other income for both the consolidated and non-consolidated accounting periods of the fiscal year ending December 31, 2024. The effects of the sale, alongside other factors, are currently being reviewed. Any necessary adjustments to...

Continue reading

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. The Company will report results from this trial and host a call with study clinical cardiology leadership to review the opportunity, early positive results, and randomized study on Tuesday, April 30, 2024, at 3:00 PM ET. Participants can register for the conference by navigating to https://dpregister.com/sreg/10188810/fc71df44d6. Please note that...

Continue reading

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock and accompanying warrant. The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described  below).  The offering was priced at-the-market under Nasdaq rules based on the average of the previous 5-days’ closing prices, or $9.84 per share which includes...

Continue reading

Calavo Growers, Inc. Provides Update to Shareholders

SANTA PAULA, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq: CVGW) (“Calavo” or the “Company”), a global avocado industry leader and provider of convenient, ready-to-eat fresh food, yesterday at its Annual Meeting of Shareholders said in a business update that:The Company has made significant progress toward completing the proposed sale of the Fresh Cut business (formerly “RFG”) and related real property and expects to close in May 2024 As previously shared, the expected uses of sale proceeds would include paying down debt and returning cash to shareholders The Company’s internal investigation into potential Foreign Corrupt Practices Act violations in Mexico is winding down and the Company will share more with investors when it is able to do soAbout Calavo Growers, Inc. Calavo Growers, Inc. (Nasdaq:...

Continue reading

Opthea to Present at the OIS Retina Innovation Summit at ARVO

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington. OIS Retina Innovation Summit DetailsSession Innovation ShowcaseDate: Saturday, May 4, 2024Time: 8:35 to 9:50 a.m. PDTPresenter: Frederic Guerard, PharmD, CEOAbout Opthea Opthea (ASX/NASDAQ:OPT)...

Continue reading

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents a comprehensive overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell (TCR-T) therapy, at CHI’s 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London. MDG1015, which is advancing towards the clinic, targets NY-ESO-1 / LAGE-1a (New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a) and is armored and enhanced by the PD1-41BB costimulatory switch protein The presentation with the title “MDG1015: a 3rd Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory Switch Protein, Advancing to the Clinic”...

Continue reading

Lakeland Financial Reports First Quarter Net Income of $23.4 Million and 5% Annualized Average Loan Growth

WARSAW, Ind., April 25, 2024 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $23.4 million for the three months ended March 31, 2024, which represents a decrease of $877,000, or 4%, compared with net income of $24.3 million for the three months ended March 31, 2023. Diluted earnings per share were $0.91 for the first quarter of 2024 and decreased 3% compared to $0.94 for the first quarter of 2023. On a linked quarter basis, net income decreased $6.2 million, or 21%, from fourth quarter 2023 net income of $29.6 million. Diluted earnings per share decreased from $1.16, or 22%. Net income for the first quarter of 2024 benefited from the recognition of $1.0 million in additional insurance recoveries associated with the wire fraud loss that...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.